SCHEMBL278513

SCHEMBL278513

OC[C@H]1OC(n2cnc3c(Cl)ncnc32)[C@H](O)C1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 7/20 0.73
STAT6 P42226 2/20 0.73
DPP4 P27487 1/20 0.73
MEN1 O00255 1/20 0.73
SLC28A1 O00337 1/20 0.73
MAP3K7 O43318 1/20 0.73
SLC28A2 O43868 1/20 0.73
GAPDH P04406 1/20 0.73
ADORA3 P0DMS8 1/20 0.73
MAPK1 P28482 1/20 0.73
ADORA2A P29274 1/20 0.73
ADORA2B P29275 1/20 0.73
ADORA1 P30542 1/20 0.73
PI4KA P42356 1/20 0.73
KMT2A Q03164 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
PI4K2B Q8TCG2 1/20 0.73
DOT1L Q8TEK3 1/20 0.73
PI4K2A Q9BTU6 1/20 0.73
SLC28A3 Q9HAS3 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL272122 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL1858029 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL19443159 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL319667 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL67126 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL10062644 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL272123 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL10340725 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL21139429 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL91050 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133879-B2 Myocardial perfusion imaging methods and compositions GILEAD SCIENCES, INC. (US) 2012-03-13 US disclosed
US-20100183503-A1 MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS GILEAD PALO ALTO, INC. 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100183503-A1 MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS ADORA2A, ADORA3, ADORA1 SLC29A1 46/4885STAT6 2249/4885DPP4 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.